	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	2	"20020004481"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:15			0
2	BRS	L2	2	"20020172661"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:16			0
3	BRS	L3	2	5977057.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:33			0
4	BRS	L4	112158	(pharmaceutical or therapeutic$2) adj composition	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:34			0
5	BRS	L5	1772	succinate same buffer	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:35			0
6	BRS	L6	125	((pharmaceutical or therapeutic$2) adj composition) same (succinate same buffer)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:35			0
7	BRS	L7	12	(((pharmaceutical or therapeutic$2) adj composition) same (succinate same buffer)) same mM	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:36			0
8	BRS	L8	46	(succinate same buffer) same composition same mM	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:36			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
9	BRS	L9	2	(succinate same buffer) same ((human adj insulin-like adj growth adj factor adj ((pharmaceutical or therapeutic$2) adj composition)) or IGF-1)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:37			0
10	BRS	L10	2186	(human adj insulin-like adj growth adj factor adj 1) or IGF-1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:38			0
11	BRS	L11	0	6 same 10	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:39			0
12	BRS	L12	0	8 same 10	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:39			0
13	BRS	L13	12	shirley adj bret.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:55			0
14	BRS	L14	18	hora adj maninder.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:55			0
15	BRS	L15	2	((shirley adj bret.in.) or (hora adj maninder.in.)) and (7 or 8)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/16 15:56			0

> d his

(FILE 'HOME' ENTERED AT 16:01:17 ON 16 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
16:01:41 ON 16 MAR 2003

L1 24950 S (PHARMACEUTIC? OR THERAPEUTIC?) (W) COMPOSITION
L2 2100 S SUCCINATE (P) BUFFER
L3 625 S (SUCCINIC ACID) (P) BUFFER
L4 2617 S L2 OR L3
L5 4 S L1 (P) L4
L6 4 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)
L7 135 S COMPOSITION (P) L4
L8 92 DUPLICATE REMOVE L7 (43 DUPLICATES REMOVED)
L9 8 S L8 (P) MM
L10 8 S L9 NOT L6
L11 20744 S (HUMAN INSULIN-LIKE GROWTH FACTOR 1) OR (IGF-1)
L12 0 S L11 (P) (L5 OR L9)

=> log y

```
FILE 'HOME' ENTERED AT 16:01:17 ON 16 MAR 2003

=> file medline caplus biosis embase scisearch agricola
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:01:41 ON 16 MAR 2003

FILE 'CAPLUS' ENTERED AT 16:01:41 ON 16 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:01:41 ON 16 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:01:41 ON 16 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:01:41 ON 16 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 16:01:41 ON 16 MAR 2003

=> s (pharmaceutic? or therapeutic?) (w) composition
L1       24950 (PHARMACEUTIC? OR THERAPEUTIC?) (W) COMPOSITION

=> s succinate (p) buffer
L2        2100 SUCCINATE (P) BUFFER

=> s (succinic acid) (p) buffer
L3         625 (SUCCINIC ACID) (P) BUFFER

=> s l2 or l3
L4        2617 L2 OR L3

=> s l1 (p) l4
L5           4 L1 (P) L4

=> duplicate remove l5
PROCESSING COMPLETED FOR L5
L6           4 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> d l6 1-4 ibib abs

L6   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2002:256088  CAPLUS
DOCUMENT NUMBER:          136:299709
TITLE:                    Tocol-based compositions containing amiodarone
INVENTOR(S):              Lambert, Karel J.; Kessler, Dean R.; Nienstedt, Andrew
                          M.; Hartgraves, Greg A.; Constantinides, Panayiotis P.
PATENT ASSIGNEE(S):       Sonus Pharmaceuticals, Inc., USA
SOURCE:                   PCT Int. Appl., 21 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002026324      A2   20020404       WO 2001-US30320  20010927
     WO 2002026324      A3   20020704
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001094826 A5 20020408 AU 2001-94826 20010927
PRIORITY APPLN. INFO.: US 2000-235865P P 20000927
WO 2001-US30320 W 20010927

AB ***Pharmaceutical*** ***compns*** . comprising amiodarone or one of its prodrugs or analogs and one or more tocols are disclosed. An emulsion contained amiodarone 0.6, d,l-.alpha.-tocopherol 1.0, tocopherol polyethylene glycol ***succinate*** 1.0, Poloxamer P-407 0.5, PEG-400 g, and ***buffer*** q.s. 50 mL. Stability of the formulations was studied.

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:121156 CAPLUS
DOCUMENT NUMBER: 124:156044
TITLE: Pharmaceutical compositions containing hGH.
INVENTOR(S): Samaritani, Fabrizio
PATENT ASSIGNEE(S): Applied Research Systems, Neth.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535116	A1	19951228	WO 1994-IT86	19940617
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 804223	A1	19971105	EP 1994-920573	19940617
EP 804223	B1	19990922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 10504531	T2	19980506	JP 1994-501903	19940617
AT 184798	E	19991015	AT 1994-920573	19940617
ES 2139081	T3	20000201	ES 1994-920573	19940617
US 5898030	A	19990427	US 1996-750684	19961217

PRIORITY APPLN. INFO.: EP 1994-920573 19940617
WO 1994-IT86 19940617

AB Pharmaceutical compns. contg. hGH were stabilized by saccharose. The formulation is particularly suitable for stabilizing a lyophilizate of recombinant hGH.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:532058 CAPLUS
DOCUMENT NUMBER: 122:274053
TITLE: Process and apparatus for manufacturing of a pharmaceutical composition containing prednisolone sodium succinate, suitable for parenteral dosing
INVENTOR(S): Mago Karacsony, Erzsebet; Ambrus, Gabor; Balogh, Tibor; Danitz, Bela; Toldy, Lajos; Makk, Nandor; Tegdes, Aniko; Kovacs, Klara Maria; Bidlo, Gaborne; et al.
PATENT ASSIGNEE(S): Gyogyszerkutato Intezet, Hung.
SOURCE: Hung. Teljes, 14 pp.
CODEN: HUXXBU
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 66012	A2	19940829	HU 1992-4081	19921222
HU 212306	B	19960528		

PRIORITY APPLN. INFO.: HU 1992-4081 19921222

AB The process involves mixing prednisolone hemisuccinate and NaOH, sterile filtering of the resultant prednisolone sodium succinate soln., filling it into ampuls, lyophilizing it, and closing the ampuls under an inert gas atm. Thus, powd. prednisolone hemisuccinate with a particle size .ltoreq.200 .mu.m is dispersed in an aq. soln. contg. (9.5.+-.0.2):(0.5.+-

.0.2) wt.:wt. Na2HPO4 and NaH2PO4 as buffer substances. The dispersion is cooled to 5-15.degree., preferably to 5-10.degree.. Then 80-95%, preferably 85-95%, of the stoichiometrically necessary 0.3-1.0% wt.:vol. NaOH soln. is added in portions during intensive stirring of the reaction medium and stirring is continued until the complete dissoln. of prednisolone hemisuccinate. A stainless steel reactor for carrying out the process is also claimed. In contrast to former processes this process gives only trace amts. of hydrolysis products at most.

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:62635 CAPLUS
DOCUMENT NUMBER: 112:62635
TITLE: Stabilized injection solutions containing nonlyophilized gamma-interferons
INVENTOR(S): Hwang-Felgner, Jiin Yu; Jones, Richard E.; Maher, James F.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8904177	A1	19890518	WO 1988-US3883	19881101
W: AU, DK, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
IL 88233	A1	19930818	IL 1988-88233	19881030
AU 8827245	A1	19890601	AU 1988-27245	19881101
AU 621327	B2	19920312		
EP 386106	A1	19900912	EP 1988-910211	19881101
EP 386106	B1	19940302		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500882	T2	19910228	JP 1988-509401	19881101
JP 2732877	B2	19980330		
AT 102048	E	19940315	AT 1988-910211	19881101
ZA 8808249	A	19900725	ZA 1988-8249	19881103
DD 289470	A5	19910502	DD 1988-321429	19881103
CA 1335176	A1	19950411	CA 1988-582102	19881103
US 5151265	A	19920929	US 1990-514392	19900425

PRIORITY APPLN. INFO.: US 1987-116434 19871103
EP 1988-910211 19881101
WO 1988-US3883 19881101

AB A liq. ***pharmaceutical*** ***compn*** . comprises an effective amt. of nonlyophilized .gamma.-interferon. The compn. further includes a ***buffer*** capable of maintaining the pH within 4-6, polyhydric sugar alcs. as stabilizer, and a nonionic detergent. The relative shelf-life for the liq. contg. 2 mg/mL .gamma.-interferon, mannitol, and ***succinate*** ***buffer*** was 10 days as compared to 1 day for the lyophilized formulation.

=> d his

(FILE 'HOME' ENTERED AT 16:01:17 ON 16 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:01:41 ON 16 MAR 2003
L1 24950 S (PHARMACEUTIC? OR THERAPEUTIC?) (W) COMPOSITION
L2 2100 S SUCCINATE (P) BUFFER
L3 625 S (SUCCINIC ACID) (P) BUFFER
L4 2617 S L2 OR L3
L5 4 S L1 (P) L4
L6 4 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> s composition (p) l4
L7 135 COMPOSITION (P) L4

=> duplicate remove l7
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L7
L8 92 DUPLICATE REMOVE L7 (43 DUPLICATES REMOVED)

=> s l8 (p) mM
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L49 (P) MM'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L55 (P) MM'
L9 8 L8 (P) MM

=> s l9 not l6
L10 8 L9 NOT L6

=> d l10 1-8 ibib abs

L10 ANSWER 1 OF 8 MEDLINE
ACCESSION NUMBER: 88307898 MEDLINE
DOCUMENT NUMBER: 88307898 PubMed ID: 2457334
TITLE: Separation of cell organelles in density gradients based on their permeability characteristics.
AUTHOR: Gasser K W; DiDomenico J; Hopfer U
CORPORATE SOURCE: Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio 44106.
CONTRACT NUMBER: AM 25170 (NIADDK)
DK 27651 (NIDDK)
HL 07415 (NHLBI)
SOURCE: ANALYTICAL BIOCHEMISTRY, (1988 May 15) 171 (1) 41-6.
Journal code: 0370535. ISSN: 0003-2697.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198809
ENTRY DATE: Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19880915
AB The buoyant density of intracellular organelles is dependent in part on the nature of the ***buffer*** ***composition*** of the density gradient and the permeability characteristics of the organelle membrane to the constituents of this ***buffer*** . Therefore, knowledge of the transport properties of different organelles allows the design of density gradients useful for their purification. We have used this approach to significantly decrease mitochondrial contamination of pancreatic zymogen granules in a one-step purification procedure on a 40% Percoll density gradient. These gradients, prepared with isoosmotic sucrose, yield a narrow band of zymogen granules and mitochondria. However, by substitution of sucrose with salts to which mitochondria but not zymogen granules are permeable, the densities of mitochondria are altered to give a significant separation. For example, the incorporation of 100 ***mM*** sodium ***succinate*** in the Percoll gradient can produce a 70% reduction in mitochondrial contamination. The increased ionic strength has an additional beneficial effect on zymogen granule yield by 5-10%. The recognition and utilization of transport pathways in organelle membranes is the principal feature of this technique and should prove to be widely applicable to other isolation procedures.

L10 ANSWER 2 OF 8 MEDLINE
ACCESSION NUMBER: 83238332 MEDLINE
DOCUMENT NUMBER: 83238332 PubMed ID: 6305947
TITLE: The regulation of extramitochondrial steady state free Ca2+ concentration by rat insulinoma mitochondria.
AUTHOR: Prentki M; Janjic D; Wollheim C B
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1983 Jun 25) 258 (12) 7597-602.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198308
ENTRY DATE: Entered STN: 19900319

Last Updated on STN: 19970203
Entered Medline: 19830811

AB For the study of Ca2+ handling by mitochondria of an insulin secretory tissue, a method for the isolation of functionally intact insulinoma mitochondria is described. The mitochondria had a respiratory control ratio of 6.3 +/- 0.3 with ***succinate*** as a substrate. The regulation of extramitochondrial [Ca2+]o concentration by suspensions of insulinoma mitochondria was studied using Ca2+-selective minielectrodes. The mitochondria were found to maintain an ambient free Ca2+ concentration of about 0.3 and 0.9 microM in the absence or presence of Mg2+ (1 ***mM***), respectively. The addition of Na+ resulted in a dose-dependent (half-maximal 4 ***mM*** Na+) increase in steady state [Ca2+]o. Na+ accelerated the ruthenium red-induced Ca2+ efflux, suggesting the existence of a Ca2+/2Na+ antiporter, as described in mitochondria of excitable tissues. Experiments were performed to study the effects of various agents on the steady state extramitochondrial free Ca2+. cAMP, 3-isobutyl-1-methylxanthine, and NADH were found to have no effect, whereas phosphoenolpyruvate induced a net Ca2+ efflux, the kinetic of which suggests deleterious effects on mitochondrial functions. A small decrease in pH (0.1 unit) of the incubation ***buffer*** resulted in an increase of the extramitochondrial Ca2+ steady state that was reversible upon restoration of the pH to its initial value. In conclusion, insulinoma mitochondria were able to maintain an extramitochondrial [Ca2+]o steady state in the submicromolar range that was markedly influenced by the ionic ***composition*** of the incubation medium. Thus, mitochondria may play a role in the regulation of cellular calcium homeostasis and insulin release.

L10 ANSWER 3 OF 8 MEDLINE
ACCESSION NUMBER: 83230736 MEDLINE
DOCUMENT NUMBER: 83230736 PubMed ID: 6860312
TITLE: Photosynthetic electron transport in thylakoid preparations from two marine red algae (Rhodophyta).
AUTHOR: Stewart A C; Larkum A W
SOURCE: BIOCHEMICAL JOURNAL, (1983 Feb 15) 210 (2) 583-9.
Journal code: 2984726R. ISSN: 0264-6021.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198307
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 19900319
Entered Medline: 19830729

AB Thylakoid membrane preparations active in photosynthetic electron transport have been obtained from two marine red algae, Griffithsia monilis and Anotrichium tenue. High concentrations (0.5-1.0 M) of salts such as phosphate, citrate, ***succinate*** and tartrate stabilized functional binding of phycobilisomes to the membrane and also stabilized Photosystem II-catalysed electron-transport activity. High concentrations (1.0 M) of chloride and nitrate, or 30 ***mM*** -Tricine/NaOH ***buffer*** (pH 7.2) in the absence of salts, detached phycobilisomes and inhibited electron transport through Photosystem II. The O2-evolving system was identified as the electron-transport chain component that was inhibited under these conditions. Washing membranes with ***buffers*** containing 1.0-1.5 M-sorbitol and 5-50 ***mM*** concentrations of various salts removed the outer part of the phycobilisome but retained 30-70% of the allophycocyanin 'core' of the phycobilisome. These preparations were 30-70% active in O2 evolution compared with unwashed membranes. In the sensitivity of their O2-evolving apparatus to the ***composition*** of the medium in vitro, the red algae resembled blue-green algae and differed from other eukaryotic algae and higher plants. It is suggested that an environment of structured water may be essential for the functional integrity of Photosystem II in biliprotein-containing algae.

L10 ANSWER 4 OF 8 MEDLINE
ACCESSION NUMBER: 76260253 MEDLINE
DOCUMENT NUMBER: 76260253 PubMed ID: 783158
TITLE: Effect of cations and anions on the steady state kinetics of energy-dependent Ca2+ transport in rat liver mitochondria.

AUTHOR: Hutson S M; Pfeiffer D R; Lardy H A
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1976 Sep 10) [redacted] (17) 5251-8.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197611
ENTRY DATE: Entered STN: 19900313
Last Updated on STN: 19970203
Entered Medline: 19761101

AB The divalent cation ionophore A23187 has been used to investigate the kinetics of energy-dependent Ca2+ uptake by rat liver mitochondria under steady state conditions. During A23187-induced cyclic Ca2+ flux, the free Ca2+ concentration is adjusted using [ethylenebis(oxyethylenenitrilo)]tetraacetic acid (EGTA) ***buffers*** . The rate of Ca2+ transport, which is inferred from the rate of ***succinate*** oxidation, is a function of the free Ca2+ concentration in the medium. The kinetics are sigmoidal with the free Ca2+ concentration at half-maximal respiratory stimulation (K0.5) equal to 3.1 +/- 0.4 muM at 25 degrees. The maximal Ca2+-stimulated respiratory rate (Vmax) is a function of the ionic ***composition*** of the medium. Magnesium and Mg2+ plus phosphate produced a parallel stimulation of the maximal respiration rate whether activated by Ca2+ uptake or by the uncoupler carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP). In the absence of A23187, Ca:O rations of 4.0 were obtained under most experimental conditions. Magnesium is a potent competitive-like inhibitor, increasing the K0.5 for Ca2+ to 30.0 muM at 2.0 ***mM*** MgCl2. Magnesium dramatically decreases the apparent affinity for Ca2+ but does not appear to alter the kinetic mechanism. In contrast, the alkali metal cations are weak inhibitors, at most doubling the K0.5 for Ca2+; however, they antagonized Mg2+ inhibition with an order of effectiveness Li+ greater than or equal to Na+ greater than K+ greater than Rb+ =Cs+. Phosphate and acetate increased the Vmax slightly without altering the K0.5 for Ca2+. Phosphate did not influence the inhibitory effects of Mg2+ or Mg2+ plus K+. This study suggests that during steady state conditions, the maximal rate of Ca2+ accumulation is primarily electron transport-limited. The results are also discussed in terms of a possible physiological role for Mg2+ and K+ in the intracellular regulation of energy-dependent mitochondrial Ca2+ transport in liver.

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:79106 CAPLUS
DOCUMENT NUMBER: 120:79106
TITLE: Manufacture of transparent moldings with hard surface
INVENTOR(S): Uenishi, Michiharu; Nagai, Shoichi; Takei, Masatoshi; Kobayashi, Yukio; Akagi, Juji
PATENT ASSIGNEE(S): Mitsubishi Rayon Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05228431	A2	19930907	JP 1992-32341	19920219

PRIORITY APPLN. INFO.: JP 1992-32341 19920219

AB Title moldings, useful for building, automotive, and optical applications (no data), are manufd. by irradiating moldings bearing on surface a layer of polymers derived from monomers contg. .gtoreq.2 (meth)acryloyl groups and other monomers with UV light of wavelengths .ltoreq.300 nm, treating the irradiated moldings with alkali to generate .gtoreq.0.02 .mu.mol acidic groups/cm2 on the surface, coating the surface with hydrolytic polycondensation products of XaSi(OY)4-a (X = epoxy-contg. functional group; Y = hydrocarbyl; a = 1-3) and/or SiR1bR2c(OR3)d [R1, R2 = (ether or ester linkage-contg.) hydrocarbyl; R3 = H, hydrocarbyl; b, c = 0-3; d = 4 - b - c = 1-4; b + c = 1-3], and contacting the polycondensation products with a high-temp. fluid at .gtoreq.500.degree.. Thus, a 2 ***mm*** -thick PMMA sheet was dip-coated with a soln. contg. dipentaerythritol

hexaacrylate 10, equimolar ***succinic*** ***acid*** -trimethylolethane-acrylic ac[redacted] condensation product 20, tetrahydrofurfuryl acrylate 5, Darocur 1173 1.2, isopropanol 34, and toluene 20% and irradiated with UV (365 nm, 840 mJ/cm2) at 35.degree. to form a 3.5 .mu.m-thick film with pencil hardness 5H, which was further UV-irradiated (254 nm, 1300 mJ/cm2) and immersed in 20% aq. NaOH to generate 0.05 .mu.mol acidic groups/cm2. The sheet was dip-coated with a ***compn*** . of .gamma.-glycidoxypropyltrimethoxysilane 100.4, isopropanol 278.3, tetraethoxysilane 40.0, 0.2 N AcOH/NaOAc (***buffer*** , pH 5) 22.9, and Mg perchlorate 2.0 parts, held at 100.degree. for 3 h, then brought into contact with a natural gas flame of 900.degree. 20 times for .apprx.0.2 s each time. The cured coat showed good Taber abrasion resistance, cross-cut adhesion 100/100 initially and 100/100 after 20-h immersion in H2O at 80.degree., and smooth crack-free surface before and after the hot water immersion.

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:639540 CAPLUS
DOCUMENT NUMBER: 111:239540
TITLE: Liposomes containing hydrophilic drugs and a process for manufacture them
INVENTOR(S): Profitt, Richard Thomas; Adler-Moore, Jill; Chiang, Su-Ming
PATENT ASSIGNEE(S): Vestar, Inc., USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 317120	A1	19890524	EP 1988-310278	19881101
EP 317120	B1	19910828		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8824161	A1	19890518	AU 1988-24161	19881024
AU 598958	B2	19900705		
AT 66598	E	19910915	AT 1988-310278	19881101
ES 2029330	T3	19920801	ES 1988-310278	19881101
KR 9707187	B1	19970507	KR 1988-14547	19881105
NO 8804989	A	19890516	NO 1988-4989	19881109
NO 178484	B	19960102		
NO 178484	C	19960410		
JP 01160915	A2	19890623	JP 1988-284828	19881110
JP 2958774	B2	19991006		
CA 1339008	A1	19970325	CA 1988-582730	19881110
DK 8806293	A	19890513	DK 1988-6293	19881111
US 5965156	A	19991012	US 1995-469251	19950606

PRIORITY APPLN. INFO.: US 1987-119518 A 19871112
EP 1988-310278 A 19881101
US 1990-600154 A1 19901019

AB A novel liposome ***compn*** . and a method for solubilizing amphiphilic drugs in a small amt. of org. solvent for use in improved liposomes are described. A phosphatidylglycerol is acidified and the amphiphilic drugs suspended in an org. solvent are added to solubilize the drugs. Distearoylphosphatidylglycerol Na soln. dissolved in CHCl3-MeOH mixt. (1:1) was acidified with HCl and then mixed with amphotericin B (I) soln. dissolved in the same solvent. Hydrogenated egg phosphatidylcholine soln. and cholesterol soln. dissolved in the same solvent were then mixed with the mixt. The pH was adjusted to 4.5 by addn. of 2.5 N NaOH. The molar ratio of I, distearoylphosphatidylglycerol, hydrogenated egg phosphatidylcholine, and cholesterol in the soln. was 0.4, 0.4, 2.0, and 1.0 resp. The lipid soln. was spray-dried to give a powder, which was hydrated with 9% lactose-contg. 10 ***mM*** ***succinate*** ***buffer*** (pH 5.62) and sonicated to give liposomes. Mice were i.v. inoculated with Candida albicans and 3 days post-infection, mice were treated with a single dose of either free I or liposomal I. There was no dose level of free I which produced any survivors at 29 days post-infection; however, all animals treated with 10 or 15 mg/kg of liposomal I were still alive 42 days post-infection.

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:5807 CAPLUS
DOCUMENT NUMBER: 111:180738
TITLE: Sustained-release pharmaceuticals containing a soluble metoprolol salt and a dihydropyridine in a gel-forming matrix
INVENTOR(S): Ragnarsson, Gert Anders; Silfverstrand, Kajsa Margareta; Sjoegren, John Albert
PATENT ASSIGNEE(S): Aktiebolag Haessle, Swed.
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 311582	A1	19890412	EP 1988-850319	19880922
EP 311582	B1	19930113		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8822374	A1	19890413	AU 1988-22374	19880916
AU 615211	B2	19910926		
AT 84412	E	19930115	AT 1988-850319	19880922
ES 2053815	T3	19940801	ES 1988-850319	19880922
NO 8804269	A	19890410	NO 1988-4269	19880927
NO 177375	B	19950529		
NO 177375	C	19950906		
US 4942040	A	19900717	US 1988-250945	19880929
IL 87922	A1	19930708	IL 1988-87922	19881005
DK 8805586	A	19890409	DK 1988-5586	19881006
FI 8804636	A	19890409	FI 1988-4636	19881007
FI 92903	B	19941014		
FI 92903	C	19950125		
JP 01128917	A2	19890522	JP 1988-252209	19881007
CA 1312286	A1	19930105	CA 1988-579566	19881007
CN 1032490	A	19890426	CN 1988-109129	19881008
CN 1029935	B	19951011		

PRIORITY APPLN. INFO.: SE 1987-3881 19871008
EP 1988-850319 19880922

AB A controlled-release pharmaceutical for once daily administration contains metoprolol and a poorly water-sol. Ca channel blocking agent of the dihydropyridine type; metoprolol is included in the form of small beads contg. as the main sol. component a salt of metoprolol coated with a water-insol. polymeric membrane. The dihydropyridine is dispersed in a nonionic solubilizer. Both, the dispersed dihydropyridine and the metoprolol-contg. beads are incorporated in a matrix forming a swelling agent when in contact with water. A mixt. contg. felodipine, Polyoxyl-40 hydrogenated castor oil (solubilizer), Polyvydon-K90, hydroxypropyl Me cellulose (swelling agent), Al silicate, lactose, and microcryst. cellulose was granulated with EtOH and dried. Metoprolol ***succinate*** was sprayed onto cores of SiO2 to form beads (0.5 ***mm*** diam.) and the beads were coated by spraying with a soln. contg. Et cellulose, hydroxypropyl Me cellulose in CH2Cl2/iso-PrOH; the beads and granules were mixed, a lubricant was added and the ***compn*** . was pressed into tablets. Tablets contg. 10 mg felodipine and 95 mg metoprolol ***succinate*** each were prepd. from a mixt. contg. felodipine 10, Polyoxyl-40 25, Polyvydon-K90 24, hydroxypropyl Mg cellulose 230, Al silicate 94, lactose 56, microcryst. cellulose 6, metoprolol ***succinate*** 95, SiO2 24, Et cellulose 32, and addl. hydroxypropyl Me cellulose 8 g. The dissoln. rate of felodipine in phosphate ***buffer*** contg. 1% Na dodecyl sulfate was 14, 64, 88, and 98% after 2, 8, 12, and 20 h, resp.; the dissoln. rater of metorpolol ***succinate*** was 5, 39, 65, and 95% after 2, 8, 12, and 20 h, resp. Suitable polymers for coating the beads are Eudragit RL, Eudragit RS, alone or in combination; Et cellulose in combination with hydroxypropyl Me cellulose or hydroxypropyl cellulose is preferred.

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:118245 CAPLUS
DOCUMENT NUMBER: 106:118245
TITLE: Freshness of fish and shellfish. II. Modified simple

colorimetry of dehydrogenase activity in shellfish using tetrazolium chloride

AUTHOR(S): Tsunoda, Kojun; Inoue, Noriko; Aoyama, Mitsuo; Hasebe, Akihisa

CORPORATE SOURCE: Suginami Ward Inst. Public Health, Tokyo, 168, Japan

SOURCE: Shokuhin Eiseigaku Zasshi (1986), 27(5), 487-91
CODEN: SKEZAP; ISSN: 0015-6426

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB A simple colorimetry procedure for the detn. of dehydrogenase [9035-82-9] activity in shellfish was based on redn. of triphenyltetrazolium chloride (TTC) to triphenylformazan (TF). The dehydrogenase activity in shellfish muscle is low. When pH 7.4 phosphate ***buffer*** was added to the TTC reagent, dehydrogenase activity in shellfish muscle was increased markedly. The best ***compn*** . of TTC reagent was 0.2% TTC-0.1% Na ***succinate*** -2.84% Na2HPO4-2.34% NaCl. A sample of shellfish muscle was sliced about 1.5 ***mm*** thick, soaked in TTC reagent, incubated at 37.degree. for 30 min, cooled, extd. with EtOH, filtered, and measured at 284 nm. It was also possible to det. dehydrogenase activity in oyster gills by using this TTC reagent.

=> d his

(FILE 'HOME' ENTERED AT 16:01:17 ON 16 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:01:41 ON 16 MAR 2003

```
L1        24950 S (PHARMACEUTIC? OR THERAPEUTIC?) (W) COMPOSITION
L2         2100 S SUCCINATE (P) BUFFER
L3          625 S (SUCCINIC ACID) (P) BUFFER
L4         2617 S L2 OR L3
L5            4 S L1 (P) L4
L6            4 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)
L7          135 S COMPOSITION (P) L4
L8           92 DUPLICATE REMOVE L7 (43 DUPLICATES REMOVED)
L9            8 S L8 (P) MM
L10           8 S L9 NOT L6
```

```
=> s (human insulin-like growth factor 1) or (igf-1)
   4 FILES SEARCHED...
L11      20744 (HUMAN INSULIN-LIKE GROWTH FACTOR 1) OR (IGF-1)
```

```
=> s l11 (p) (l5 or l9)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L73 (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L76 (P) '
L12           0 L11 (P) (L5 OR L9)
```

=> d his

(FILE 'HOME' ENTERED AT 16:01:17 ON 16 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:01:41 ON 16 MAR 2003

```
L1        24950 S (PHARMACEUTIC? OR THERAPEUTIC?) (W) COMPOSITION
L2         2100 S SUCCINATE (P) BUFFER
L3          625 S (SUCCINIC ACID) (P) BUFFER
L4         2617 S L2 OR L3
L5            4 S L1 (P) L4
L6            4 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)
L7          135 S COMPOSITION (P) L4
L8           92 DUPLICATE REMOVE L7 (43 DUPLICATES REMOVED)
L9            8 S L8 (P) MM
L10           8 S L9 NOT L6
L11       20744 S (HUMAN INSULIN-LIKE GROWTH FACTOR 1) OR (IGF-1)
L12           0 S L11 (P) (L5 OR L9)
```

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```